Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were purchased at an average cost of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the purchase, the insider now owns 5,698,799 shares of the company’s stock, valued at approximately $149,593,473.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Radius Health, Inc. (NASDAQ RDUS) opened at $28.32 on Friday. Radius Health, Inc. has a one year low of $24.66 and a one year high of $55.30. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same period last year, the firm earned ($1.07) earnings per share. equities analysts anticipate that Radius Health, Inc. will post -5.4 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/19/radius-health-inc-rdus-major-shareholder-buys-1312500-00-in-stock.html.

Several hedge funds and other institutional investors have recently modified their holdings of RDUS. Principal Financial Group Inc. raised its holdings in shares of Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 180 shares during the period. Teachers Advisors LLC raised its holdings in shares of Radius Health by 4.4% in the first quarter. Teachers Advisors LLC now owns 54,024 shares of the biopharmaceutical company’s stock worth $2,088,000 after buying an additional 2,289 shares during the period. Vanguard Group Inc. raised its holdings in shares of Radius Health by 3.2% in the first quarter. Vanguard Group Inc. now owns 3,010,646 shares of the biopharmaceutical company’s stock worth $116,362,000 after buying an additional 93,188 shares during the period. Geode Capital Management LLC raised its holdings in shares of Radius Health by 6.8% in the first quarter. Geode Capital Management LLC now owns 299,263 shares of the biopharmaceutical company’s stock worth $11,566,000 after buying an additional 19,085 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after buying an additional 2,628,070 shares during the period.

A number of equities analysts recently commented on the company. Cantor Fitzgerald set a $58.00 price target on Radius Health and gave the company a “buy” rating in a research note on Sunday, July 23rd. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $45.00 price objective on shares of Radius Health in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $51.00.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.